The 3 Best Stocks to Invest $1,000 in Right Now

By Thomas Niel – Mar 6, 2026 at 2:00PM ESTKey PointsBrookfield Corporation trades at a discount to its assets and holdings, and its value could continue to compound in the coming years.SSR Mining remains one of the best ways to capitalize on rising precious metals prices.Teva Pharmaceuticals is pivoting from generic drugs to branded specialty treatments.Numerous factors are affecting the stock market right now. However, many long-term opportunities remain. Some stocks benefit from current trends, whether they be rising spot gold prices or accelerating adoption of generative artificial intelligence (AI). There are also stocks benefiting from trends unaffected by the macroeconomic and geopolitical backdrop. While these stocks are not necessarily immune to near-term market volatility, buying them today could prove very profitable in the long run. Three stocks that come to mind are Brookfield Corporation (BN 3.07%), SSR Mining (SSRM 2.12%), and Teva Pharmaceuticals (TEVA 2.21%). Even if you only have $1,000 today to put toward a long-term portfolio, each stock is a great choice. Image source: Getty Images. Brookfield is an undervalued compounding machine Canada-based holding company Brookfield Corporation may seem complicated.In addition to its majority stake in its well-known Brookfield Asset Management (BAM 2.52%) subsidiary, Brookfield also holds interests in a variety of public and privately held investment vehicles managed by the asset management unit. ExpandNYSE: BNBrookfield CorporationToday's Change(-3.07%) $-1.30Current Price$41.19Key Data PointsMarket Cap$105BDay's Range$40.44 - $41.6052wk Range$29.07 - $49.56Volume258KAvg Vol5MGross Margin26.37%Dividend Yield0.56% Brookfield has also vastly expanded its insurance operations, focusing on profiting from the long-term investment of its insurance assets, similar to Berkshire Hathaway's objective when it comes to owning insurance companies . For years, Brookfield's management has noted that the company trades at a discount to the underlying value of its holdings. This valuation discount persists and could continue to do so. Even so, as management also anticipates more than 20% earnings growth over the next five years, such growth could help close the valuation gap, resulting in strong price appreciation. SSR Mining could thrive in uncertain times As geopolitical tensions escalate, spot gold prices spiked yet again. That's good news for those holding physical gold in their portfolios, but for those owning precious metals stocks, higher gold prices could have an outsized impact on their investments. ExpandNASDAQ: SSRMSSR MiningToday's Change(-2.12%) $-0.66Current Price$30.53Key Data PointsMarket Cap$6.3BDay's Range$29.85 - $31.3652wk Range$8.65 - $33.49Volume3.8MAvg Vol3.9MGross Margin35.73% That's the bull case for SSR Mining. The production-stage gold mining company's fiscal performance improved substantially last year, thanks to gold surging from $3,000 to over $5,000 per ounce. In 2025, this high-double-digit increase in gold prices resulted in more than a sevenfold adjusted earnings growth Following the latest gold spike, SSR's stock price has hit new highs. However, don't assume shares have topped out. Multiple factors point to gold remaining at elevated prices, if not moving higher. If high gold prices are here to stay, SSR Mining could rise on both higher earnings and valuation expansion. Currently, the stock trades for less than 9 times forward earnings, while other mining stocks such as Barrick Mining trade at forward multiples in the mid-teens . Teva's transformation is still unfolding Israel-based Teva Pharmaceuticals has been a generic drugmaker. In recent years, the company has pivoted to become a branded pharmaceutical company, especially in specialty drugs and treatments. ExpandNYSE: TEVATeva Pharmaceutical IndustriesToday's Change(-2.21%) $-0.70Current Price$31.05Key Data PointsMarket Cap$36BDay's Range$30.74 - $31.4052wk Range$12.46 - $37.34Volume7.7MAvg Vol9.4MGross Margin51.82% Teva's generics business is experiencing little to no growth, but its branded drug business is growing at a mid-double-digit clip. As more of the company's drug pipeline advances through clinical trials and regulatory approval, Teva should remain positioned to sustain steady sales and profitability growth. This growth, along with the move from generic to branded products, could lead to a further reassessing the value of shares. Teva currently trades for 12.5 times forward earnings, but a mid-teens forward multiple could be warranted, given the valuation of other faster-growing pharmaceutical stocks.Read NextMar 2, 2026 •By Matt DiLalloWant $1 Million In Retirement? Invest $100 a Month in These 3 Stocks and Don't Look Back.Feb 22, 2026 •By Matt DiLalloHere's My Highest Conviction AI Stock to Buy Right Now (HINT: It Recently Partnered with Nvidia)Feb 18, 2026 •By Matt DiLallo1 Financial Stock That Could Turn $250 Per Month Into $1.4 MillionFeb 17, 2026 •By Thomas Niel3 Things Every Brookfield Investor Needs to KnowFeb 14, 2026 •By Jason Hall3 Stocks I'd Happily Hold Through Any Stock Market CrashFeb 14, 2026 •By Matt DiLalloThis Wealth-Creating Machine Continues to Deliver Strong ResultsAbout the AuthorThomas Niel is a contributing Analyst at The Motley Fool, covering publicly traded companies in the consumer goods and technology sectors. Prior to the Motley Fool, Thomas was a contributing Analyst for several online investing publications, including InvestorPlace, Seeking Alpha, and TipRanks. He also has past career experience in the accounting and government contracting industries. He holds a B.B.A. in Accounting from Marymount University. Thomas won his school's geography bee in the fifth grade, but retired from the professional geography bee circuit shortly thereafter.TMFThomasNielStocks MentionedBrookfield CorporationNYSE: BN$41.19(-3.07%)-$1.31Teva Pharmaceutical IndustriesNYSE: TEVA$31.05(-2.21%)-$0.70Berkshire HathawayNYSE: BRKA$748,191.01(-0.34%)-$2,558.89Berkshire HathawayNYSE: BRKB$499.04(-0.27%)-$1.36Barrick MiningNYSE: B$45.40(+0.09%)+$0.04SSR MiningNASDAQ: SSRM$30.53(-2.12%)-$0.66Brookfield Asset ManagementNYSE: BAM$46.07(-2.52%)-$1.19*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.